Pasithea Therapeutics Corp. reports news centered on PAS-004, its next-generation macrocyclic MEK inhibitor, and the company’s clinical-stage biotechnology operations. Recurring updates cover NF1-associated plexiform and cutaneous neurofibromas, advanced cancer, ALS-related research, FDA designations, clinical development strategy and medical leadership.
Company news also includes capital actions, investor conference presentations and public-company matters tied to common stock and warrant securities. Pasithea’s releases frame the business around drug-development progress, regulatory designations and financing activity supporting research, preclinical work and clinical trials.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Pasithea Therapeutics Corp. (KTTA) announced that Prof. Lawrence Steinman will deliver a keynote address at the AAAS Annual Meeting on March 4, 2023. Prof. Steinman's research linking the Epstein-Barr virus to multiple sclerosis (MS) was recognized as a runner-up for the 2022 Science Magazine Breakthrough of the Year.
The company's PAS-002 program aims to develop a DNA plasmid vaccine targeting GlialCAM, a protein implicated in MS, providing potential treatment avenues for this chronic autoimmune disease affecting 2.8 million worldwide.
Pasithea Therapeutics Corp. announced that Lawrence Steinman, Chairman, will deliver a significant lecture at the ACTRIMS Forum in San Diego on February 23, 2023. The event, themed “MS: Going Viral,” focuses on the role of the Epstein-Barr virus in Multiple Sclerosis (MS), which relates to the Company's PAS-002 drug discovery program. PAS-002 aims to create an engineered DNA plasmid vaccine targeting GlialCAM, a protein implicated in MS. MS affects 2.8 million people globally, with relapsing remitting MS being the most common type. Steinman's research was recognized as a runner-up for Science Magazine’s 2022 Breakthrough of the Year.
Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced that its Chairman, Prof. Lawrence Steinman, will receive the 2023 Pioneer in Medicine Award for significant contributions to brain mapping and therapeutics at the 20th Annual Gathering for the Cure on February 17, 2023. This award is presented by the Society for Brain Mapping & Therapeutics (SBMT) and the World Brain Mapping Foundation, recognizing pioneering work in fields like multiple sclerosis (MS). The company is focusing on developing a proprietary engineered DNA plasmid vaccine, PAS-002, targeting GlialCAM for MS treatment, affecting over 2.3 million people worldwide.